ACCU-CHEK COMPACT PLUS BLOOD GLUCOSE MONITORING SYSTEM

K081389 · Roche Diagnostics · NBW · Jul 15, 2008 · Clinical Chemistry

Device Facts

Record IDK081389
Device NameACCU-CHEK COMPACT PLUS BLOOD GLUCOSE MONITORING SYSTEM
ApplicantRoche Diagnostics
Product CodeNBW · Clinical Chemistry
Decision DateJul 15, 2008
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 862.1345
Device ClassClass 2

Intended Use

The ACCU-CHEK Compact Test Drums are used with the ACCU-CHEK Compact or Compact Plus Meter. The ACCU-CHEK Compact and Compact Plus systems are designed to quantitatively measure the concentration of glucose in capillary and venous whole blood. The devices are indicated for professional use and over-the-counter sale. The ACCU-CHEK Compact and Compact Plus systems are indicated for lay use with capillary whole blood samples drawn from the fingertips, forearm, upper arm, thigh, calf, and palm.

Device Story

System measures glucose concentration in capillary and venous whole blood; utilizes test drums with meter. Designed for professional and lay use; enables self-monitoring of blood glucose. Input: whole blood sample applied to test strip. Output: quantitative glucose concentration displayed on meter. Modifications from predicate include ergonomic/physical design and electronic/hardware changes. System includes lancing device for sample collection. Healthcare providers use output to assess glycemic control; patients use output for diabetes management.

Clinical Evidence

Bench testing only. Comparison of system accuracy performance demonstrated substantial equivalence to the predicate device. System maintains compliance with EN ISO 15197. Design verification testing confirmed performance, safety, and effectiveness are equivalent to the predicate.

Technological Characteristics

Glucose monitoring system consisting of meter, test drums, control solutions, and lancing device. Fundamental scientific technology unchanged from predicate. Compliance with EN ISO 15197.

Indications for Use

Indicated for professional and lay users for quantitative measurement of glucose in capillary and venous whole blood. Capillary samples may be obtained from fingertips, forearm, upper arm, thigh, calf, and palm.

Regulatory Classification

Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K081389 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ## ACCU-CHEK® Compact Plus Blood Glucose Monitoring System: 510(k) Summary | Sponsor | Roche Diagnostic<br>9115 Hague Road<br>Indianapolis, IN 46250 U.S.A. | |--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Correspondent | Scott Thiel<br>Roche Diagnostic<br>9115 Hague Road<br>Indianapolis, IN 46250<br>Phone: (317)521-2000 | | Device Name<br>and<br>Classification | ACCU-CHEK® Compact Plus Blood Glucose Monitoring System<br>Common Name: glucose test system<br>Classification:<br>1. ACCU-CHEK Compact Plus Blood Glucose Meter and ACCU-CHEK Compact Test Strips are Class II devices (21 CFR § 862.1345)<br>2. ACCU-CHEK Compact Control Solutions are a Class I device (21 CFR § 862.1600)<br>3. ACCU-CHEK Softclix Lancing Device with ACCU-CHEK Softclix lancets are Class I (exempt) devices (21 CFR § 878.4800) | | System<br>Description | The ACCU-CHEK Compact Plus Blood Glucose Monitoring System consists of the ACCU-CHEK Compact Plus Meter, ACCU-CHEK Compact Test Strips (provided separately), ACCU-CHEK Compact Control Solutions (provided separately), ACCU-CHEK Softclix lancing device, and ACCU- CHEK Softclix lancets.<br>The ACCU-CHEK Compact Plus meter and ACCU-CHEK Softclix lancing device are modifications of the ACCU-CHEK Compact meter and ACCU- CHEK Softclix lancing device, respectively.<br>There are no changes to other system testing components compared to the currently marketed product. | | | Continued on next page | : {1}------------------------------------------------ ## ACCU-CHEK® Compact Plus Blood Glucose Monitoring System: 510(k) Summary, Continued | Predicate<br>Device | ACCU-CHEK Compact Blood Glucose Monitoring System. | |----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Intended Use | The ACCU-CHEK Compact Test Drums are used with the ACCU-CHEK<br>Compact or Compact Plus Meter. The ACCU-CHEK Compact and Compact<br>Plus systems are designed to quantitatively measure the concentration of<br>glucose in capillary and venous whole blood. The devices are indicated for<br>professional use and over-the-counter sale. The ACCU-CHEK Compact and<br>Compact Plus systems are indicated for lay use with capillary whole blood<br>samples drawn from the fingertips, forearm, upper arm, thigh, calf, and palm. | | Comparison to<br>Predicate<br>Device | The modifications to the device encompass:<br>Meter: ergonomic/physical design and electronic/hardware changes. Lancing device: ergonomic/physical design Control solution: color | | | There have been no changes to the test strips, intended use, indications for<br>use, operating principle, or functionality. | | Technological<br>Characteristics | There has been no change to the fundamental scientific technology. | | Summary of<br>Performance<br>Characteristics | There has been no change to the performance characteristics of the system.<br>A comparison of system accuracy performance demonstrated that the ACCU-<br>CHEK Compact Plus system and the currently marketed ACCU-CHEK<br>Compact system are substantially equivalent. The system maintains<br>compliance with EN ISO 15197.<br>Design verification testing confirmed that the performance, safety, and<br>effectiveness of the ACCU-CHEK Compact Plus system are equivalent to the<br>predicate device. | | Conclusion | The ACCU-CHEK Compact Plus system is substantially equivalent to the<br>predicate ACCU-CHEK Compact blood glucose monitoring system. | : {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three stripes representing the department's mission to promote health, well-being, and human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Roche Diagnostics c/o Mr. Scott Thiel Regulatory Affairs Program Manager 9115 Hague Road Indianapolis, IN 46256 JUL 1 5 2008 Re: k081389 Trade Name: ACCU-Chek Compact Plus Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose Monitoring System Regulatory Class: Class II Product Codes: NBW, LFR Dated: July 7, 2008 Received: July 8, 2008 Dear Mr. Thiel: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {3}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97), You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours. Jean M. Cooper, M.S., D.V.M. Jean M. Cooper, M.S., D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indication for Use 510(k) Number (if known): k081389 Device Name: Accu-Chek Compact Plus Blood Glucose Monitoring System Indication For Use: The Accu-Chek Compact Test Drums are used with the Accu-Chek Compact or Compact Plus Meter. The Accu-Chek Compact and Compact Plus system is designed to quantitatively measure the concentration of glucose in capillary and venous whole blood. The device is indicated for professional use and over-the-counter sale. The Accu-Chek Compact and Compact Plus system are indicated for lay person use with capillary whole blood samples drawn from the fingertips, forearm, upper arm, thigh, calf, and palm. Prescription Use (21 CFR Part 801 Subpart D) And/Or Over the Counter Use X (21 CFR Part 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) Off Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K011389
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%